Chongqing Pharscin Pharmaceutical (002907.SZ) has obtained the registration certificate for the drug Butorphanol Tablets.
Huasen Pharmaceuticals (002907.SZ) announced that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the company's product Butyrophenone Hydrochloride Tablets (5mg and 15mg).
Chongqing Pharscin Pharmaceutical (002907.SZ) announced that the company has recently received the "Drug Registration Certificate" for its product Sertraline Hydrochloride Tablets (5mg and 15mg) approved and issued by the National Medical Products Administration.
As a non-benzodiazepine class anti-anxiety medication, Sertraline Hydrochloride Tablets are a serotonin (5-HT1A) receptor agonist. Its mechanism of action involves selectively binding to 5-HT1A receptors in the brain to reduce excessive 5-HT activity in patients with anxiety disorders, thereby exerting an anti-anxiety effect. Multiple clinical trials have shown that compared to traditional benzodiazepine class medications, Sertraline Hydrochloride Tablets can significantly alleviate patients' anxiety symptoms. Additionally, this medication has the characteristics of being non-sedating, non-muscle relaxant, non-addictive, and does not affect cognitive function, demonstrating good tolerability and safety.
Related Articles
XD INC (02400) spent around HKD 7.9024 million to repurchase 118,000 shares on March 23rd.
BINHAI INV (02886) spent HK$322,800 on March 23 to repurchase 290,000 shares.
.png)
BOE Varitronix (00710) announced its performance for 2025, with a net profit attributable to shareholders of HK$345 million, a decrease of approximately 12% year-on-year. The final dividend is HK$0.153 per share.
XD INC (02400) spent around HKD 7.9024 million to repurchase 118,000 shares on March 23rd.
BINHAI INV (02886) spent HK$322,800 on March 23 to repurchase 290,000 shares.
BOE Varitronix (00710) announced its performance for 2025, with a net profit attributable to shareholders of HK$345 million, a decrease of approximately 12% year-on-year. The final dividend is HK$0.153 per share.
